Small Animal MR Facility, Last Updated 6/1/2010 Documentation to assist in developing an Animal Use Protocol for Small Animal MR. Investigators intending to use the UGA small animal imaging facilities for in vivo studies are required to have an approved Animal Use Protocol (AUP) that includes the use of MR prior to initiating research. Information below is to assist in addressing some
Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.
Erityisesti laatu viagra tästä kaupasta voi taata henkilökohtaisesti cialis Paras laatu kehotan Teitä miellyttää.
Microsoft word - ajms.3.3.2010.195-200.docO R I G I N A L A R T I C L E
A l A m e e n J M e d S c i ( 2 0 1 0 ) 3 ( 3 ) : 1 9 5 - 2 0 0 Vaginal Misoprostol in Early Pregnancy Failure
Suguna R.Kumar*,Vidya A Thobbi and Shafia Shafi
Department of Obstretrics & Gynecology, Al Ameen Medical College & Hospital, Abstract: Early pregnancy failure (EPF) occurs in 10-15% of clinically diagnosed
pregnancies. 65% of these women are not willing for surgical evacuation. Medical evacuation
is gaining acceptance as a treatment of option than surgical or expectant management. This is
a prospective clinical trial of 150 pregnant women with EPF of <13weeeks gestation managed
by 400µg of vaginal misoprostol 4hourly to a maximum of 3 doses. Failure to expel the
products of conception in 24 hours, excessive bleeding per vagina and incomplete expulsion
were managed by surgical evacuation. Complete and incomplete evacuation was confirmed
by transvaginalsonography (TVS). All surgical evacuations done under I.V. sedation required
no anesthesia because of the cervical priming effect of misoprostol. Tolerable prostaglandin
side effects were seen and no women required blood transfusion. Acceptance of medical
management is 89%. Successful complete medical evacuation occurred in 86%, completely
failed in 7.3%, incomplete evacuation in 3.3% and 3.3% underwent emergency surgical
evacuation for excessive bleeding per vagina. Misoprostol, an antiulcer drug is still not
approved by FDA for EPF management. But acceptance of medical management in EPF is
89%, it is economical without the surgical complication of anesthesia, uterine perforation,
infection and uterine adhesions. Thus instead of going for expectant management, medical
management has definitely a role in EPF in women not willing for surgical evacuation.
Keyword: medical evacuation, vaginal misoprostol, early pregnancy failure.
EPF affects 1 in 4 women during her lifetime, or 1 in 9 clinically recognized pregnancies [1-2]. Prompt surgical evacuation of the uterus recommended in the past because of the risk of infection and coagulation disorder [3-4]. An emotional aspect of losing a pregnancy, especially in nillipara and conception following infertility makes surgical evacuation not acceptable. Surgical management carries the risk of anesthesia, being nil by mouth, bed occupancy when waiting for a convenient O T list, uterine perforation, intrauterine adhesions, cervical trauma, infection and infertility . Expectant management of waiting for spontaneous expulsion is an option, but success rate being suboptimal (25-75%), prolonged follow up of 4weeks required . Uncertainty in its time of expulsion requiring unplanned surgical curettage which cannot be practiced when assess to the medical care is far requiring transportation. In women who do not accept surgical management medical management is the treatment of choice. Misoprostol has been studied as a solo agent in the management of miscarriage. Following are some potential treatment regimens for misoprostol as a solo agent 800µg vaginally up to 2 doses, 24 hours apart. Effectiveness range (53-93%), mean 73.8% or median ~85% [4,7-9] 600µg vaginally or orally, 2-3 total doses 24-48 hours apart. Effectiveness range 46-96%, mean 80% and median ~86% [8,10-12] 2010. Al Ameen Charitable Fund Trust, Bangalore Al Ameen J Med. Sci, Volume 3, No.3, 2010 Suguna RK et al • 400µg vaginally or orally given every 4 hours, 24 or 48 hours, up to max of 3 doses. Effectiveness range 13-95% mean 68% and median ~70 or 78% [4, 8,13-15] Misoprostol is a prostaglandin E1 analogue, 15-deoxy, 16-hydroxy, 16 methyl PGE1, water soluble, viscous liquid, rapidly absorbed from GIT, in vaginal route of administration it bypasses the GIT and hepatic metabolism, sustains a plasma levels up to 4 hours thus the dose is administered 4 hourly. The side effects are more in oral and sublingual than vaginal route [16-17]. This study is to determine the efficacy, acceptance, side effects of 400µg of 4 hourly vaginal misoprostol for a maximum of 3 doses in 24 hours. Materials and Methods
This was a prospective clinical trial on women with early pregnancy failure of <13 weeks visiting ANC clinic, Al-Ameen Women and Children Hospital from April 2007 to march 2009. Women who refused surgical evacuation were motivated for medical management, with the permission of the hospital ethical committee, written consent, these women were admitted for 24 hours for medical evacuation with 400µg of vaginal misoprostol moisten in 3 drops of distilled water every 4 hourly to a maximum of 3 doses and given a period of 24 hours for complete evacuation. Diagnostic criteria for early pregnancy failure are: (a) Fetal demise with fetal pole of at least 5-6mm without cardiac activity, (b) An embryonic pregnancy with the presence of gestational sac of >15-20mm without fetal pole or lack of interval growth on repeat sonogram after 10 days, (c) Incomplete abortion with thickened heterogeneous endometrial lining of >15mm in AP diameter without gestational sac . (d) Inevitable abortion where cervix has dilated products of conception has not been Exclusion criteria were unstable hemodynamic, s/s of pelvic infection, past h/o hypersensitivity to prostaglandins, bronchial asthma, cardiac disease, epilepsy and hypertension. Prerequisites were general physical examination, pelvic examination to note the size of uterus, cervical status and fornix. Investigations – Hbg/dl, BT, CT, blood grouping & typing (anti D administration in Rh-ve), urine-routine, TVS to diagnose EPF. Outcome noted were Induction-evacuation time interval in relation to the dose of administration of misoprostol, side effects - increased bleeding per vagina i.e., soakage of 1 pad in one hour, abdominal cramps requiring analgesia, nausea, vomiting, diarrhea, fever, chills, TVS to rule out incomplete evacuation- endometrial thickness of >15mm and complete failure to evacuate in 24 hours. Surgical evacuation done if there was increased bleeding per vagina, incomplete evacuation, complete failure to evacuate. All women were advised to report back after 14 days or if there were complaints of abdominal pain, fever, increased bleeding per vagina. The amount (soakage and number of pads changed) and duration of bleeding enquired, and repeat Hbg/dl done after 14days. 2010. Al Ameen Charitable Fund Trust, Bangalore Al Ameen J Med. Sci, Volume 3, No.3, 2010 Suguna RK et al In this study 282 women were diagnosed as EPF, 182(65%) refused surgical evacuation, 162 agreed for medical evacuation, acceptance of medical evacuation was 89%. Table No-1: reason for refusing surgical evacuation; Wanted medical evacuation, name of the drug, dose not known Thought might cause infertility in future 12 women in whom medical management was contraindicated were excluded from the study group. Mean age was 25±5.5 years, 58(38.6%) were nullipara, mean gestational age according to LMP was 9.36±1.62 weeks, mean size of uterus by pelvic examination was 8.68±2.54 weeks, mean gestational sac size was 18±2mm. Medical evacuation was successful in 129( 86%) and failed in 21(14%). Table No-2: the type of EPF and its failure rate in each type. Mean induction evacuation interval was 11.4±5.24 hours, if the women expelled with 1st dose the second dose was not repeated, 79(61.2%) women expelled after the 3rd dose. No women required oxytocics. Table No-3: The induction-evacuation interval and the dose required 2010. Al Ameen Charitable Fund Trust, Bangalore Al Ameen J Med. Sci, Volume 3, No.3, 2010 Suguna RK et al Adverse effects were nausea in 7(4.6%), vomiting in 4(2.6%), diarrhea in 3(2%), fever in 5(3.3%) which subsided with paracetamol, chills in 4(2.6%), abdominal cramps requiring analgesia (mefenemic acid and dicyclomine) in 6(6.6%), emergency evacuation in 5(3.3%). No oxytocics or anesthesia used during evacuation. Only surgical evacuated women were given antibiotics. During follow up after 14days 136 reported back and 14 were lost for follow up. Bleeding per vagina was mild to moderate with mean duration of bleeding 9.37±2.67 days, post evacuation decrease in Hbg/dl was -0.67±0.29g/dl, and only two women had less of 1.2g/dl. No complaint of fever, pain abdomen and emergency unplanned evacuation. 130(86.6%) women were satisfied with the medical evacuation and wanted to opt for the same and recommend the same to others. Discussion
El Refeay. H et al was the first to report medical management in EPF with mefipristone 600mg and oral misoprostol 600 µg after 48 hours with 90%(90% CI) success. But the nonviable and unstable decidual lining in abnormal pregnancy donot requires an antiprogestational, mifepristone. In this study 400µg vaginal misoprostol 4hourly to a maximum of 3 doses used to reduce the gastrointestinal side effect and to get the efficacy with minimum dose, time and adverse effects. TVS being the gold standard in confirmation of complete and incomplete evacuation, 90-100% sensitivity and 80-92% specificity  helps to decide about the surgical evacuation, thus decreasing the incidence of emergency unplanned admission due to bleeding per vagina and infection. No women visited with these complaints in 14 days of follow up. The failure rate after medical management in various trials ranges from 10-50% and surgical management 0-4% [5,7, 9,20-22]. Our study showed 14% failure. In our study success rate of 61.2% was after the 3rd dose and many large trials have also shown the requirement of 2nd dose administration but the dose used in these trials were 600 or 800µg [7,20,22-23]. Studies show higher failure rate of 47-50% [9, 22] when assessed in 24-48 hours than after one week with failure rate of 10-29% [7,20-21] but in our study assessment after 24 hours with TVS and admission of 24 hours helped us in the direct supervision of expulsion and prevented emergency admission and blood transfusion. No women required anesthesia during evacuation because of priming of cervix by misoprostol. Safety of medical management is comparable to surgical management as shown in two meta-analysis pooled data [6, 24]. The largest MIST trial by Trinder et al  also showed no difference in risk of infection, blood transfusion of 1% in medical group, median duration of bleeding was 11-12 days. Our study also showed no follow up complaint of fever, pain abdomen, unplanned emergency admission, no blood transfusion mean duration of bleeding was 9.37days. The mean decrease in Hb level was -0.6g/dl in our study. Trinder et al  showed no difference in Hb level from baseline. Davis et al  reported mean decrease of -0.7g/dl comparable to our study. Studies comparing routes of administration and side effects are inconsistent. Studies comparing medical and surgical or expectant management reported higher incidence of side effect in medical management [7,9,22] Bagratee J S et al and Blohm F et al compared misoprostol with placebo and showed 2010. Al Ameen Charitable Fund Trust, Bangalore Al Ameen J Med. Sci, Volume 3, No.3, 2010 Suguna RK et al no difference of side effects. EPF itself and the process of expulsion are associated with some degree of side effects [26-27]. Our study showed tolerable prostaglandin side effects. Acceptance of medical management was 86.6% in our study. Acceptability of medical management is high, 83 to 92 % want to recommend it to a friend, 70 to 93 % want to choose the same again [7,21,26,28-30]. Conclusion
Even though the success rate of medical management is 86% the acceptance of medical management is high. Admission of 24 hrs, expulsion under direct supervision combined with TVS minimizes unplanned emergency evacuation and hemorrhage in rural set up. Women opting medical management are counseled to anticipate tolerable prostaglandin side effects and expect bleeding for 14 days or longer. Risk of serious complication is low. Medical evacuation is economical compared to surgical evacuation. In women who refuse surgical evacuation, medical evacuation is the treatment of choice and slowly may become standard treatment for EPF in future. References
1. Albermann. E. Spontaneous abortion: Epidiomiology In: Stable G G TH.Eds. Spontaneous abortion: Diagnosis and treatment. Spriger-Verlag, London, United Kingdom. 1992, p 19-20. 2. Warburton. D, Fraser. F C, Spontaneous abortion in man: data from reproductive histories collected in a medical genetics unit. Am J Hum Genet 1964; 16; 1-25. 3. Scroggins KM, Smullur WD, Krishen AE, Spontaneous pregnancy loss evaluation, management and follow up counseling. Prim Care 2000; 27: 153-67. 4. Crenin MP, Schwartz JL, Guido RS, Pymar HC, Early pregnancy failure- current management concepts. Obstet Gynecol Surv 2001; 56; 105-13. 5. Constantinos Demetroulis, Ertan Saridogon, DattaKumar Kunde and Alan A. Naftalin. A prospective randomized controlled trial comparing medical and surgical treatment for early pregnancy failure. Hum Reprod 2001; 16; 22; 365-369. 6. Ciro Luise, Karen Jermy, Caroline May, Gillian Castello, William P Collins, Thomas H Bourne. Outcome of expectant management of spontaneous first trimester miscarriage: Observational study. BMJ 2002, 324; 873-875. 7. Zhang J, Gilles JM, Barnhart K. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Eng J Med 2005, 353;761-9. 8. Kovavisarach E, Jamnonsiri C. Intravaginal misoprostol 600µg and 800µg for the treatement of early pregnancy failure. Int J Gynaecol Obstet. 2005; 90: 208-12. 9. Graziosi GC, Mol BU, Ankum WM. Management of early pregnancy loss. Int J Gynaecol Obstet. 2004; 86: 337-46. 10. Tang OS, Ong CY, Tse KY. A randomized trial to compare the use of sublingual misoprostol with or without an additional one week course for the management of first trimester silent miscarriage. Hum Reprod. 2006; 21: 189-192. 11. Moodliar S, Bagratee JS, Moodley J. Medical verses surgical evacuation of first trimester spontaneous abortion. Int J Gyneacol Obstet. 2005; 91: 21-26. 12. Pandian Z, Ashok P, Templeton A. The treatment of incomplete abortion with oral misoprostol. Br J Obstret Gynecol 2001; 108: 213-4. 13. Vejborg TS, Rorbye C, Nilas L. Management of first trimester spontaneous abortion with 800µg or 400µg vaginal misoprostol. Int J Gyneacol Obstet. 2006; 92: 268-9. 2010. Al Ameen Charitable Fund Trust, Bangalore Al Ameen J Med. Sci, Volume 3, No.3, 2010 Suguna RK et al 14. Sifakis, Agelakis E, Vardaki E, Fragouli Y, Koutamkakis E. High dose misoprostol used in outpatient management of first trimester spontaneous abortion. Arch Gynecol Obstet. 2005, 272: 183-6. 15. Coughlin LB, Roberts D, Haddad NG, Long H. Medical management of first trimester incomplete miscarriage using misoprostol. Obstet Gynecol 2004, 24: 17-8. 16. Zieman M, Fong SK, Benonitz NL. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997; 90: 88-92. 17. Hardman JG, Gilman AG, Limbird LE. In: Joet G. Hardman. Lee E. Limbird eds. Goodman and Gilman’s. The Pharmacological bais of therapeutics. 9th ed. New York McGraw Hill, 1996: 914. 18. Angela Dempsey MD, MPH, Anne Davis MD, MPH. Medical management of early pregnancy loss. How to treat and what to expect. Semin Reprod Med 2008; 26(5): 401-410. 19. Wong SF, Larn MH, HOLC. Transvaginal sonography in the detection of retained products of conception after first trimester spontaneous abortion. J Clin Ultrasound. 2002; 30: 428-32. 20. Gronlund A, Gronlund L, Clevin L. Management of missed abortion. Comparison of medical treatment with either mefipristone+misoprostol or misoprostone alone with surgical evacuation. A multicenter trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand 2002; 81:1060-1065. 21. Ninimaki, Jouppila P, Martikainen H. A randomized study comparing efficacy and patient satisfaction in medical or surgical treatment of miscarriage. Fertil Steril 2006; 86:367-372. 22. Chung TK, Lee DT, Cheung LP. Spontaneous abortion: a randomized controlled trial comparing surgical evacuation with conservative management with misoprostol. Fertil Steril 1999; 71: 1054-1059. 23. Graziosi GC, van der Steeg JW, Reuwer PH. Economic evaluation of misoprostol with treatment of early pregnancy failure compared with curettage after expectant management. Human Reprod 2005; 20: 1067-1077. 24. Sotiriadis A, Makrydimus G, Papatheodorous S. Expectant, medical or surgical management of first trimester miscarriage. A meta analysis. Obstet Gynecol 2005; 105(5pt1):1104-1113. 25. Trinder J, Brocklehurst P, Porter R. Management of miscarriage: expectant, medical, surgical? Results of randomized controlled trial (miscarriage treatment (MIST) trial). BMJ. 2006; 332, 1235-1240. 26. Bagratee JS, Khullar V, Regan L. A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Hum Reprod. 2004; 19: 266-271. 27. Blohm F, Friden BE, Milsom I. A randomized double blind trial comparing misoprostol or placebo in the management of early miscarriage . Br J Obstret Gynecol 2005; 112: 1090-1095. 28. Davis AR, Hendlish SK, W esthoff C. Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure; results from a randomized trial. Am J Obst Gynecol. 2007; 196: 31-37. 29. Blanchard K. Taneepanichskul S, Kiriwat O. Two regimes of misoprostol for treatment of incomplete abortion for medical management of incomplete abortion. Contraception. 2005; 72:438-442. 30. Ngoc NT, Blum J, Westheimer E. Medical treatment of missed abortion using misoprostol. Int J Gynecol Obstet. 2004; 87; 138-142. *All correspondences to: Dr.Suguna R.Kumar, Department of Obstretrics & Gynecology, Al Ameen Medical College, Bijapur-586108, Karnataka, India.Email:firstname.lastname@example.org 2010. Al Ameen Charitable Fund Trust, Bangalore
Automatic Data Capture Systems - RFID CP4014 Internet and Communications Technology Assessment 2 By Stacey Greenaway 3.1 Overview . 5 3.2 Tags. 5 3.3 Radio Frequency . 6 6.1.1 Current Uses. 10 6.1.2 Future Uses . 10 6.2.1 Current Uses. 10 6.2.2 Future Uses . 10 6.3 Supply Chain (inc. Distribution, Retail) . 10 6.3.1 Current Uses. 10 6.3.2 Future Uses . 11 6.4.1 Current Uses. 11 6.4.2 Future